問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

National Taiwan University Hospital

List

3138Cases

2020-12-01 - 2022-06-24

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2018-08-31 - 2020-12-31

Phase II

Efficacy and safety of 3 doses of S201086/GLPG1972 administered orally once daily in patients with kneeosteoarthritis. A 52-week international, multi-regional, multicenter,randomized, double-blind, placebo-controlled, doseranging study.

  • Condition/Disease

    kneeosteoarthritis

  • Test Drug

    S201086/GLPG1972

Participate Sites
4Sites

Terminated3Sites

黃春明
China Medical University Hospital-Taipei

未分科

2012-12-01 - 2015-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2006-03-01 - 2010-03-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Study ended6Sites

2008-09-01 - 2010-02-28

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2009-09-01 - 2013-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2013-05-01 - 2015-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2011-07-01 - 2012-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2012-04-01 - 2013-11-30

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2015-06-01 - 2017-07-31

Phase II

Dose-response study of gevokizumab (S 78989) 3mg, 10 mg, 30 mg or 60 mg in patients with type 2 diabetes and diabetic kidney disease (DKD). A 66-week, international, multicenter, randomized, double-blind, placebo-controlled phase IIb study.

  • Condition/Disease

    diabetic kidney disease (DKD)

  • Test Drug

    S78989

Participate Sites
4Sites

Terminated4Sites

1 210 211 212 213 214 314
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB